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Abstract
Background: Protein methylation is recognized as a major protein modification pathway
regulating diverse cellular events such as protein trafficking, transcription, and signal transduction.
More recently, protein arginine methyltransferase activity has been shown to regulate HIV-1
transcription via Tat. In this study, adenosine periodate (AdOx) was used to globally inhibit protein
methyltransferase activity so that the effect of protein methylation on HIV-1 infectivity could be
assessed.
Results: Two cell culture models were used: HIV-1-infected CEM T-cells and HEK293T cells
transfected with a proviral DNA plasmid. In both models, AdOx treatment of cells increased the
levels of virion in culture supernatant. However, these viruses had increased levels of unprocessed
or partially processed Gag-Pol, significantly increased diameter, and displayed reduced infectivity in
a MAGI X4 assay. AdOx reduced infectivity equally in both dividing and non-dividing cells.
However, infectivity was further reduced if Vpr was deleted suggesting virion proteins, other than
Vpr, were affected by protein methylation. Endogenous reverse transcription was not inhibited in
AdOx-treated HIV-1, and infectivity could be restored by pseudotyping HIV with VSV-G envelope
protein. These experiments suggest that AdOx affects an early event between receptor binding and
uncoating, but not reverse transcription.
Conclusion: Overall, we have shown for the first time that protein methylation contributes
towards maximal virus infectivity. Furthermore, our results also indicate that protein methylation
regulates HIV-1 infectivity in a complex manner most likely involving the methylation of multiple
viral or cellular proteins and/or multiple steps of replication.
Background
Protein methylation is a post-translational modification
by which a methyl group from S-adenosylmethionine is
added to a protein. In eukaryotes, proteins can be methyl-
ated on the side chain nitrogens of arginine, lysine, and
histidine residues or on the carboxyl groups of proteins
[1]. Methylation on side chain nitrogens is considered
largely irreversible while methylation of the carboxyl
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groups is potentially reversible [2]. Peptidylarginine
deiminase activity can remove some methyl groups from
methylated arginine forming a non-charged citruline resi-
due [3-5]. Similar to other post-translational modifica-
tions, protein methylation is involved in regulating
protein-protein interactions resulting in a plethora of
effects during key cellular events, including regulation of
transcription [6-8], stress response, ageing and protein
repair [9], T-cell activation [10], nuclear transport [11],
neuronal differentiation [12,13], ion channel function
[14,15], and cytokine signaling [16].
The recent discovery of the enzyme family of the protein
arginine methyltransferases (PRMTs), as well as technical
advances that allow the specific detection of methylated
proteins [17,18] have made PRMTs of particular interest.
There are different PRMT isoforms that possess four types
of activities which transfer methyl groups from S-adeno-
syl-L-methionine (AdoMet) to the guanidino group of
arginine residues [reviewed in [19]]. PRMTs can modify
arginine residues by adding one or two methyl groups
resulting in three distinct forms of methylated arginine
residues in eukaryotes, ω-NG-monomethylarginine
(MMA), asymmetric (a) and symmetric (s) ω-NG, NG-
dimethylarginine (aDMA and sDMA). Two types of
PRMTs (type I and II) have been identified based on their
ability to catalyze the formation of dimethylarginine with
type I PRMTs resulting in aDMA and type II PRMTs result-
ing in sDMA. Both PRMT types are able to cause the for-
mation of MMA intermediates. Currently, eight PRMTs
are known in eukaryotes and they are ubiquitously
expressed. Glycine and arginine-rich (GAR) regions of
proteins are preferred substrates of type I PRMTs, while
there are no clear consensus amino acid sequences tar-
geted by type II PRMTs which are able to methylate both
isolated arginines as well as arginines within GAR regions.
Examples of cellular events affected by arginine methyla-
tion include RNA binding and processing, regulation of
transcription, signal transduction and DNA repair [18].
Much of the existing knowledge of the importance of pro-
tein methylation has been gained through the use of
methylation inhibitors which result in the accumulation
of proteins in their hypomethylated form. A variety of
adenosine analogs have been used to block both protein
and RNA methylation. The most commonly used indirect
inhibitor of protein methylation is adenosine dialdehyde,
also known as adenosine periodate (AdOx) [20-23]. Inhi-
bition of the S-adenosyl-L-homocysteine hydrolase after
the addition of AdOx to cells results in the accumulation
of S-adenosyl-L-homocysteine which in turn inhibits the
action of protein methyltransferase activities [20].
Alterations of protein methylation have been linked to
several disease states including idiopathic pulmonary
arterial hypertension, hereditary spherocytosis [24], sickle
cell anemia [25,26], cancer [27], cardiovascular disease,
spinal muscular atrophy, multiple sclerosis, and viral
infections [18].
In addition to its involvement in the pathology of dis-
eases, protein methylation has also been shown to be
important for virus replication and infectivity in a variety
of viruses. Herpes simplex virus (HSV) replication is regu-
lated, in part, by methylation of the RNA binding domain
in the HSV ICP27 protein [28]. In vaccinia virus, inhibi-
tion of protein methylation resulted in decreased virus
replication [29,30]. Protein arginine methylation has also
been shown to be required for efficient adenovirus repli-
cation [31]. Further, hepatitis delta virus antigen needed
to be methylated at arginine residues to support RNA rep-
lication [32]. In human immunodeficiency virus (HIV),
adenosine analogues have been shown to have anti-viral
activity [33]. Interestingly, arginine methylation had a
negative impact on the transactivation activity of Tat [34].
PRMT 6 activity was shown to methylate the Tat basic
domain in vitro and in vivo although the precise residues
affected are not known. Over-expression of PRMT6 pro-
tein in transfected HEK293T and HeLa MAGI cells down
regulated Tat-mediated transactivation, while cells treated
with siRNA targeting PRMT6 enhanced Tat-mediated
transactivation up to approximately 2-fold. Precisely how
PRMT6 activity impacts transactivation requires further
study.
In this study we investigated the effect of the methylation
inhibitor AdOx on the production of HIV-1 in transfected
and infected cells as well as on the infectivity of this virus
produced in the presence of AdOx. Here we demonstrate
increased virus production from transfected or acutely
infected cells in the presence of AdOx. However, HIV-1
obtained in this way exhibited defects in Gag-Pol process-
ing, altered morphology, and most importantly a consist-
ent decrease in infectivity. We further outline that the
majority of this decreased infectivity is due to the block in
HIV-1 entry steps and suggest that methylation of the HIV-
1 envelope (Env) protein may influence infectivity,
although alternative early events and other viral or cellular
proteins could be affected.
Results
AdOx treatment results in increased virus production
AdOx, an indirect inhibitor of protein methylation, was
used in order to determine if this methyltransferase inhib-
itor affected HIV-1 infectivity. Two cell models were used
including HIV-1NL4.3 infected CEM cells and HEK293T
cells transfected with the HIV-1 proviral plasmid pNL4.3.
First, the effect of AdOx on the cell proliferation and via-
bility was determined (Fig. 1A). In the presence of 5 and
10  μM AdOx, CEM cell proliferation was reduced byRetrovirology 2006, 3:92 http://www.retrovirology.com/content/3/1/92
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about half, while effects on cell viability were negligible.
However, 20 μM AdOx was moderately toxic to CEM cells
compared with the untreated control. HEK293T or
HEK293 cells treated with 10–30 μM AdOx displayed no
obvious effects on either proliferation or viability (data
not shown). However, AdOx concentrations above 30 μM
resulted in increased levels of toxicity and loss of cell
adherence was observed after prolonged exposure in
HEK293T cells. Western analysis using an anti-dimethyl-
arginine antibody confirmed that the level of protein
methylation was greatly reduced in cells treated with
AdOx (Fig. 1B).
The concentration of virus measured as virion capsid p24
protein (CAp24) present in supernatant per 105 viable
CEM cells revealed a marked increase (up to 2.5-fold at
the highest AdOx concentration) in CAp24 secretion into
culture supernatant with increasing concentrations of
AdOx (Fig. 1C). Similarly, CAp24 levels increased in
supernatant of transfected HEK293T cells (Fig. 1C).
Reverse transcriptase (RT) activity also increased in super-
natants from transfected HEK293T. RT levels in culture
supernatant collected from CEM cells did not increase
proportionate to CAp24, achieving a maximum 1.4-fold
increase at 20 μM AdOx (Fig. 1C). We also measured the
steady state level of cellular CAp24 in whole cell lysates in
either infected CEM or transfected HEK293T cells. Only
small changes in CAp24 levels were measured in
HEK293T cell lysates, while a 50% decrease in CAp24 was
noted in lysates made from infected CEM cells at 20 μM
AdOx (Fig. 1D). This result was somewhat surprising
given that the amount of secreted CAp24 was substan-
tially increased in CEM cells treated with 20 μM AdOx.
Our results are generally consistent with the recent report
that demonstrated that HIV virus production is increased
after blocking PRMT6 with siRNA [34].
The fact that increased CAp24 was evident in the superna-
tant compared to whole cell lysates also indicated that
AdOx-treatment may have increased virus assembly or
budding, or CAp24 secretion. This was examined by puri-
fying AdOx-treated and control virus through a 20%
sucrose cushion so that the amount of particulate CAp24
and RT activity could be determined. Overall, the recovery
of both proteins was remarkably similar as nearly all of
the RT activity and approximately 60% of the total CAp24
was found in pelleted virus (Fig. 1E). However, a distinct
change in the relative ratio of CAp24 to RT activity was
observed in pelleted virus, increasing from 15 to 19 (ng
CAp24:ng RT) in the presence of 20 μM AdOx (Fig. 1F).
This was not observed in transfected HEK293T in the pres-
ence of 20 μM AdOx suggesting it was a cell type specific
effect (data not shown). These results suggest that AdOx
treatment may alter either regulation of Gag synthesis or
trafficking, assembly at the membrane, or ribosomal
frameshifting, which requires further study.
Biochemical analysis of virus obtained from cells treated 
with AdOx reveals altered Gag-Pol processing
To determine whether virus produced from infected CEM
or transfected HEK293T cells in the presence of AdOx was
altered in its composition and either Gag or Gag-Pol
processing, viral lysates were separated by SDS-PAGE and
Western blotted (Fig. 2). All samples were normalized to
either CAp24 or RT. In CEM derived virus, most structural
protein and major HIV enzyme levels (RT p66 and inte-
grase) appeared unaltered in virus treated with 20 μM
AdOx compared with untreated virus samples (Fig. 2A,
CEM derived virus). The viral enzyme levels appeared
unaltered in AdOx-treated or control HEK293T cell
derived virus in similar Western blots (data not shown).
However, a small accumulation of full length or partially
processed Gag-Pol precursor was consistently observed in
5 independent CEM-derived and 3 HEK293T-derived
virus stocks using either a human anti-HIV immunoglob-
ulin (HIV-Ig) (Fig 2A) or a monoclonal antibody specific
for Gag (Fig. 2B).
Finally, Western blot analysis was performed using HIV-Ig
or a goat anti-HIV-1 polyclonal antibody to confirm that
the 100 to 170 kDa proteins present in the virion lysates
obtained from infected CEM cells were not Env (Fig. 2C).
Therefore, whole cell lysates were prepared from Chinese
hamster ovary (CHO) cells or CHO cells stably expressing
high levels of NL4.3 Env. The lysates were probed by West-
ern analysis using procedures identical to those used for
the virion lysates (Fig 2A). It was noted that the HIV-Ig
antibody did not detect Env under these conditions (Fig.
2C).
Taken together, these results show that AdOx treatment
has small effects on Gag-Pol processing resulting in
increased amounts of Gag-Pol in virus particles.
The virus ultrastructure is altered in the presence of AdOx
To further assess what effect AdOx treatment has on virus
structure, a cell pellet of day 8 infected CEM cells grown in
the presence or absence of 20 μM AdOx for 48 hours was
thin-sectioned, epon embedded and assessed by transmis-
sion electron microscopy (TEM) (Fig. 3). TEM showed
numerous virions in each sample and typical viral assem-
bly structures were observed in both control (Fig. 3A, top
panel) and AdOx-treated cells (Fig. 3A, bottom panel). In
all sections examined, virus production was only observed
in morphologically normal cells. Using the maximum
diameter, 191 control virions were measured which had a
diameter of 103 ± 13.8 nm, with a characteristic electron
dense viral core structure (Fig. 3B and 3C). We measured
223 virions produced by AdOx-treated CEM cells whichRetrovirology 2006, 3:92 http://www.retrovirology.com/content/3/1/92
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The effect of AdOx on HIV-1 production in CEM T-cells and HEK293T cells Figure 1
The effect of AdOx on HIV-1 production in CEM T-cells and HEK293T cells. A) CEM cell confluence and viability was assessed 
using a trypan blue exclusion assay and counting with a hemocytometer. The cell confluence and viability measured in two inde-
pendent assays and the standard deviation of the mean are shown. B) Western blot of cell lysates from transfected HEK293T 
cells with the anti-asymmetric dimethylarginine antibody ASYM24 demonstrating a clear reduction in amounts of methylated 
proteins present in cells treated with 10 μM AdOx compared with cells not treated with AdOx. C) Culture supernatant from 
the treated CEM cells were assayed for CAp24 and RT content. Shown are representative results from two experiments with 
the standard deviations of the mean shown. HEK293T cells were transfected with the proviral plasmid pNL4.3 and treated 
with AdOx as described in the Materials and Methods. Culture supernatant from treated HEK293T cells were assayed for 
CAp24 and RT content 48 h post transfection. Shown are representative results from two experiments with the standard devi-
ation of the mean shown. D) Whole cell lysates were prepared from infected CEM or transfected HEK293 cells. CAp24 was 
measured by ELISA of serially diluted lysates and total protein concentration was determined by Bradford assay. Shown is the 
CAp24 concentration/mg total protein. These experiments were performed from two to four times and the standard deviation 
of the mean is shown. E) HIV-1 produced by control and AdOx-treated CEM cells were partially purified by ultracentrifugation 
through a 20% sucrose cushion. The viral pellet was resuspended in RT lysis buffer and the RT and CAp24 levels were meas-
ured. The concentration of the initial filtered supernatant, and the amount of residual CAp24 and RT were also measured so 
that the % recovery could be determined. This experiment was performed twice and a representative result is shown. F) The 
ratio of the absolute values measured in (E) are shown.
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Western blot analysis of partially purified HIV-1 obtained from AdOx-treated cells Figure 2
Western blot analysis of partially purified HIV-1 obtained from AdOx-treated cells. A) HIV-1 obtained from AdOx-treated or 
control CEM T-cells was pelleted through a 20% sucrose cushion. The pelleted virus was solubilized in RT lysis buffer and the 
CAp24 concentration was determined by ELISA. Western blot analysis was performed using 20 ng of CAp24 and probed with 
a human HIV-Ig. The proteins detected by the serum were visualized by ECL and two exposures at 2 minutes (left panel) and 
20 seconds (right panel) are shown. The short exposure highlights that the amount of total virion protein was equal. The 
experiment was performed five times with similar results. B) HEK293T cells were treated with 20 μM AdOx 24 h. Equivalent 
amounts of HIV-1 obtained from cells was purified by centrifugation through 20% sucrose and resuspended in Berman Lysis 
buffer. After SDS-PAGE, western blot analysis was performed using a monoclonal CAp24 antibody. The results show one of 
three independent experiments that gave similar results. C) Whole cell lysates prepared from CHO cells or CHO cells stably 
expressing HIV-1 Env protein subunits gp120 and gp41 were analyzed by Western blot using a goat-anti HIV-1 polyclonal anti-
body (right panel) or HIV-Ig (left panel).
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had a statistically significant larger maximum diameter of
116.6 ± 18.2 nm (p < 10-10). Interestingly, we measured
16 virions with a diameter of 140–180 nm (Fig. 3D–F,
arrowed) in AdOx-treated samples, while only 3 similarly
sized virions were observed in the untreated cell sections
(Fig 3B and 3C, arrowed). Larger particles would contain
more CAp24 partially explaining why the CAp24:RT ratio
increased (Fig 1F), but only if the incorporation of Gag-
Pol precursors were not proportionally increased as well.
At least one AdOx-treated virion appeared to have two
core structures (Fig. 3E). Virus particles that contain two
cores have previously been reported to occur as frequent
as 33% in MT4 cells [35]. It is possible that methylation of
either a viral protein, or a cellular protein, such as a class
E vacuolar sorting protein [reviewed in [36]], may be
required in order to control the size and the morphology
of the assembled virus structure. Further experiments are
warranted to determine how AdOx alters the cell milieu
resulting in HIV-1 particles of increased size.
The presence of AdOx during virus production affects viral 
infectivity
The multinuclear-activation galactosidase indicator
(MAGI) assay using the MAGI-X4 cell line was used to
determine the infectivity of virus produced in the presence
of AdOx in a single round infectivity assay. When virus
produced in infected CEM or transfected HEK293T cells in
the presence of AdOx was used to infect MAGI-X4 cells, its
infectivity was consistently reduced (Fig. 4A and 4B). The
reduction in infectivity was similar in dividing and growth
arrested MAGI-X4 cells (Fig. 4B). In growth arrested
MAGI-X4 cells, the pre-integration complex (PIC) has to
be actively imported into the nucleus in order to allow
HIV infection. Hence, the lack of difference in infectivity
tends to suggest that PIC nuclear import is not a key factor
in the AdOx-induced infectivity changes. To rule out that
the observed effects were due to AdOx being present in the
virus particle or supernatant, we also performed infections
in MAGI-X4 cells pre-treated for 6 or 24 h with a single
dose of 10 μM AdOx prior to infection with NL4.3 virus
obtained from HEK293T cells without AdOx addition
(Fig. 4C). We used this concentration as it greatly
exceeded the concentrations present in the small virus
inocula which were diluted into normal tissue culture
medium. Interestingly, when MAGI-X4 cells were pre-
treated 24 hours prior to infection, a reduction of infectiv-
ity to 60% of untreated cells was observed in both divid-
ing and growth-arrested cells. This effect was observed
irrespective of whether the virus used was obtained in the
absence or in the presence of 10 μM AdOx (data not
shown), strongly indicating that AdOx present in the virus
supernatant does not affect infectivity. These results
clearly establish that the effect on infectivity observed
with virus obtained from cells in the presence of AdOx is
not due to incorporated AdOx which consequently exerts
its effect on the MAGI-X4 cells. Another point to note is
that infectivity was not altered in dividing cells if MAGI-
X4 cells were pre-treated for only 6 h prior to infection,
whereas a reduction in infectivity was detectable in
growth-arrested cells under the same conditions (Fig. 4C).
This suggests that protein methylation of cellular proteins
is more important in non-dividing cells and hence a larger
effect on infectivity can be observed.
Vpr overcomes AdOx-induced defects in infectivity in non-
dividing cells
The HIV-1 nuclear import protein viral protein R (Vpr)
plays a critical role in maintaining infectivity in non-
dividing cells [reviewed in [37]]. As our previous results
demonstrated no significant differences in virus infectivity
in dividing and non-dividing cells in the MAGI-X4 assay
(see Fig 4B), we wanted to examine if other viral proteins,
in the absence of Vpr, were affected by AdOx resulting in
altered infectivity in dividing or non dividing cells. MAGI-
X4 cells were infected with NL4.3VprFS virus, which lacks
Vpr, obtained from HEK293T cells in the presence of
AdOx. It was observed that infectivity was consistently
decreased further than observed with NL4.3 wild type
virus (compare Fig 5A and 4B). In addition, differences
between infectivity in dividing and growth arrested MAGI-
X4 cells were more pronounced, with infectivity being
more reduced in growth arrested cells compared with
dividing cells (Fig 5A). When protein methylation was
inhibited by AdOx, infectivity was reduced to a greater
extent in non-dividing cells. This suggests that (i) the Vpr
protein is not affected by protein methylation, and (ii)
that PIC nuclear import in the absence of Vpr is depend-
ent on protein methylation while Vpr-mediated nuclear
PIC import is not. Hence, Vpr can partially overcome pro-
tein methylation inhibitor induced defects in infectivity of
non-dividing cells. In the absence of Vpr, the viral proteins
MA and IN are involved in nuclear import of the PIC in
non-dividing cells [37] and our data suggest that MA or
IN-mediated PIC nuclear import is regulated by protein
methylation.
A pseudotyped envelope relieves the AdOx-induced 
decrease in virus infectivity
To determine whether AdOx treatment affected HIV-1
entry into MAGI-X4 cells, the infectivity experiment in the
MAGI-X4 cell line was repeated with vesicular stomatitis
virus G-protein (VSV-G) pseudotyped NL4.3 virus
obtained from transfected HEK293 cells. VSV-G pseudo-
typed virus does not contain HIV envelope glycoproteins
and enters cells independent of CD4 and co-receptor
interactions via endocytosis. VSV-G pseudotyped and wild
type NL4.3 virus stocks were each normalized to RT activ-
ity and then used to infect MAGI-X4 cells. Interestingly,
VSV-G pseudotyped virus produced in the presence of 10
μM AdOx was as infectious as pseudotyped virus pro-Retrovirology 2006, 3:92 http://www.retrovirology.com/content/3/1/92
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TEM of infected CEM cells Figure 3
TEM of infected CEM cells. Control (A top panel, B, and C) or AdOx-treated HIV-1 infected CEM (A bottom panel, D E, and 
F) were thin sectioned and examined by TEM. A) Viewed at 100,000 × showing typical HIV-1 assembly structures. B and C) 
Viewed 100,000 × and 50,000 ×, respectively, show HIV-1 that are primarily ~100 nm in diameter. A large HIV particle (~150 
nm) observed in control sections is indicated by an arrow in B. D) Viewed at 50,000 × shows many typical HIV-1 particles. Two 
larger virus particles with a diameter of ~150 to ~180 nm are depicted by the arrows. Large HIV-1 particles were present in all 
sections of AdOx treated cells and two more examples are shown in E and F (both at 100,000 ×). E depicts a particle which 
appears to contain two core structures.
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Infectivity of virus produced in the presence of AdOx in a single round replication assay in MAGI-X4 cells Figure 4
Infectivity of virus produced in the presence of AdOx in a single round replication assay in MAGI-X4 cells. A) MAGI-X4 cells 
were infected with HIV-1 produced in AdOx-treated CEM cells normalized to 0.1 ng virion associated RT levels. The cells 
were infected for 2 h after which the virus was removed. After 48 h, the cells were fixed and developed as described in Mate-
rials and Methods. The number of blue foci were counted by light microscopy. B) Virus was obtained 48 h post transfection 
from HEK293T cells treated once with 10 μM AdOx 6 h post transfection. MAGI X4 cells (dividing or γ-irradiated cells) were 
infected with HIV-1 normalized to RT activity. The cells were infected in a small volume and fresh media was added after 2h 
without removing virus. After 48 hr, the cells were fixed and developed as described in Materials and Methods. The number of 
blue foci were counted by light microscopy. C) MAGI-X4 cells were pretreated with a single dose of 10 μM AdOx at 6 or 24 
hours before infection with untreated NL4.3 virus. Cells were infected with virus normalized to RT activity. For all experi-
ments, each infection was performed in duplicate. The experiments were performed at least twice using independent virus 
stocks. The average result and standard deviation of the mean are shown for experiments in A-C.
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AdOx inhibition acts through Vpr and envelope Figure 5
AdOx inhibition acts through Vpr and envelope. A) γ-irradiated or untreated HeLa MAGI-X4 cells were infected with a NL4.3 
Vpr-negative HIV molecular clone (pNL4.3VprFS) produced in HEK293T cells treated with AdOx as indicated. Cells were 
infected with virus normalized to RT activity. Each infection was performed in duplicate. The experiment was performed 5 and 
4 times for 10 μM and 30 μM AdOx, respectively, using independent virus stocks. Shown are the average results and the stand-
ard deviation of the mean. B) HEK293 cells were transfected with pNL4.3 or pNL4.3env- co-transfected with a plasmid 
expressing VSV-G envelope. HeLa MAGI-X4 cells were infected with equal amounts of each virus normalized to 1 ng virion RT. 
Shown are the average % infectivity values for three independent experiments and the standard deviation of the mean. The % 
infectivity value for each AdOx treated virus is shown relative to its respective untreated virus infectivity, with the infectivity of 
each untreated virus being expressed as 100%. C) HIV-1 infected CEM cells were treated with AdOx as previously described 
(Fig. 1). ERT reactions were performed using AdOx-treated or control HIV-1. In addition as a control, untreated HIV-1 were 
supplied exogenous 1 mM AdOx to show that AdOx does not affect ERT. Reverse transcription was initiated by addition of 
deoxynucleotides and 0.1 mM Triton X-100. The HIV-1 cDNA products were recovered and negative strand strong stop DNA 
was quantitated by real-time PCR. The copy number indicated was normalized to total RT activity in the virus supernatant. The 
experiment was performed three times and the standard deviation of the mean is indicated. D) Pelleted virus produced in 
AdOx -treated or control HEK293T cells were resuspended in Berman lysis buffer. Equal amounts of each virus normalized for 
RT activity were analyzed by western blot using an anti-gp120 envelope antibody.
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duced in the absence of AdOx, strongly suggesting AdOx-
mediated effects occurred via Env, or inhibited an early
event that was bypassed via the endosomal entry pathway
(Fig. 5B). In these experiments, we noted that 10 μM
AdOx consistently inhibited infectivity by 40% whereas
the same AdOx concentration in a previous experiment
inhibited infectivity by ~20%. Irrespective of this differ-
ence, the results here agree that AdOx can reduce HIV-1
infectivity, but can be bypassed if entry is mediated via the
endosomal pathway. This implies that AdOx treatment
results in a block somewhere between receptor binding or
viral uncoating.
Endogenous reverse transcription (ERT) reactions were
performed to determine if virions had a defect in the abil-
ity to initiate DNA synthesis (Fig 5C). Three virus prepara-
tions were compared: HIV-1 NL4.3 made by HEK293T
cells treated with 10 μM AdOx (final concentration of 1
μM in the ERT reaction), untreated HIV-1 NL4.3 supple-
mented with 1 μM AdOx, or untreated HIV-1 NL4.3 with-
out AdOx. The ERT was initiated by the addition of 0.1
mM Trition-X-100 and deoxynucleotides, and the cDNA
products were measured by quantitative PCR using oligo-
nucleotides specific for a HIV-1 negative strand strong-
stop DNA, the first product of reverse transcription. No
statistically significant differences were observed in the
ability to initiate DNA synthesis in AdOx-treated or con-
trol HIV-1 (p = 0.83) (Fig. 5C). It is highly unlikely that a
reverse transcription defect is responsible for the
decreased infectivity induced by AdOx treatment.
To determine whether AdOx affected the amount of enve-
lope glycoprotein incorporated into virus particles in the
producer cells, viral lysates produced in HEK293T cells in
the presence or absence of a single addition of 10 μM
AdOx were analyzed by Western blot using a monoclonal
gp120 antibody. No significant differences in the amount
of glycoprotein incorporated into virus particles were
observed in virus produced from HEK293T cells (Fig 5D)
or HEK293 cells (data not shown), suggesting that AdOx
treatment may inhibit an early entry step such as receptor
binding or fusion rather than the incorporation of Env
into virions.
Discussion
It is becoming increasingly apparent that protein methyl-
ation is particularly important in many key cellular events
and recent studies have suggested that viral replication can
be regulated by protein methylation [6,29,30,33,34]. In
particular, HIV-1 replication has been shown to be inhib-
ited by adenosine analogues suggesting an important role
for protein methylation [33]. More recently, it was shown
that the HIV-1 Tat protein can be methylated on arginine
residues by PRMT6 [34]. In their study, Boulanger et al.
specifically reduced cellular levels of PRMT6 using siRNA
which resulted in Tat arginine methylation inhibition and
consequently increased virus production from HEK293T
cells. Here, the non-specific methylation inhibitor AdOx
was used to globally inhibit protein methylation in cells
during the production of virus in two different systems,
either in transfected HEK293T cells or in infected CEM
cells. Consistent with findings by Boulanger et al., we also
detected an increase in the amount of virus produced in
both systems of virus production (Fig 1), indicating that
blocking protein methylation in virus producing cells
results in an increase in virus output in two different cell
types and in both infected as well as transfected cells. The
major focus of this study was to determine whether pro-
tein methylation (other than Tat) was important for virus
infectivity and involved the further characterization of
virus produced in cells when protein methylation was
inhibited by AdOx.
Firstly, it was demonstrated that the major structural pro-
teins and enzymes were present in virus produced in CEM
cells when protein methylation was inhibited by AdOx
(Fig. 2). In addition, we detected an increase in the relative
ratio of CAp24 to RT in virus produced in AdOx-treated
CEM cells indicating that protein methylation affected
virus assembly. Curiously this was not observed in
HEK293T cells suggesting this effect was cell type depend-
ent. Secondly, there were detectable differences in virus
protein composition detected between virus produced in
cells in the presence or absence of AdOx where an increase
of Gag-Pol and partially processed intermediates in CEM
and in HEK293T cells were observed by Western blot (Fig.
2). The increase in the amount of Gag-Pol precursor in
both CEM and HEK293T cells suggests that a defect in the
cleavage of the Gag-Pol intermediate may be affected by
protein methylation. Irrespective of the exact mechanism
and cause for the observed alterations in Gag-Pol process-
ing in the presence of AdOx, it is unlikely that these subtle
differences detected in either of the cell lines are the main
reason for the observed effects on virus infectivity (Fig. 4).
Curiously, TEM showed that AdOx treated HIV-1-infected
CEM cells made larger particles indicating that a methyla-
tion pathway somehow contributes to viral particle for-
mation. It was recently estimated that an increase in virion
diameter from 119 nm to 207 nm increased CAp24 con-
tent from 3,000 to 11,000 molecules [39]. Using similar
calculations, we estimate that approximately 1800 CAp24
molecules were present in a control virion and approxi-
mately 2900 CAp24 molecules in an AdOx-treated virion.
This may at least partially account for the increased ratio
of CAp24 to RT measured in AdOx treated virions. Why
RT levels were relatively lower compared to CAp24 in
CEM cells is not clear but possible explanations include
that AdOx may alter RT frame shifting or RT trafficking to
assembling virions. It is not clear how protein methyla-Retrovirology 2006, 3:92 http://www.retrovirology.com/content/3/1/92
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tion could impact on virion size and whether this is due
to protein methylation of a viral or cellular protein, or an
altered cell transcriptome.
Despite the increase in virus production in the presence of
AdOx from both cell types (see Fig. 1), virus produced in
the presence of AdOx displayed altered infectivity in a sin-
gle round replication assay (Fig. 4). The effect on infectiv-
ity was dependent on the concentration of AdOx present
during virus production, with reduced infectivity at higher
AdOx concentrations in both dividing and growth
arrested cells. This effect was observed irrespective of the
cell type used to produce the virus. Although AdOx was
moderately toxic to CEM cells at 20 μM and not toxic to
293T cells, virus biochemistry was only modestly affected
in both cell types (increased levels of CAp24 in CEM, low
amounts of unprocessed Gag-Pol in both cell types)
clearly separating cellular toxicity from virion composi-
tion defects. It was noted during the TEM examination of
all cell sections that virus production was only observed in
morphologically healthy looking cells, and not in apop-
totic or necrotic cells. We ruled out that these effects were
due to AdOx being incorporated into virions and exerting
its effect on the infected MAGI-X4 cells, by exposing
MAGI-X4 cells to AdOx prior to infection with non-
treated virus. Moreover, AdOx does not block methylation
directly but inhibits synthesis of the important precursor
molecule homocysteine. It is extremely unlikely that suffi-
cient AdOx could be present in the small virus inocula to
deplete the endogenous pools of S-adenosyl methionine
in the MAGI-X4 cells. These results strongly suggest that
protein methylation of one or more of the proteins
present in the virus particle can regulate virus infectivity.
Interestingly, the cellular factor Sam68 can bind to the Rev
response element of HIV-1 and functionally replace or
synergize with Rev to regulate the transport of unspliced
HIV-1 mRNA [40-42]. Sam-like proteins, including SLM-
1, SLM2, and others, also have the ability to replace Rev
function [reviewed in [43]]. Recently, it was shown that
PRMT1 uses Sam68 as a substrate leading to asymmetric
dimethylarginine formation [44]. Methylation was
required for Sam68 function and inhibition with 250 μM
AdOx resulted in cytoplasmic accumulation of Sam68 and
decreased transport of unspliced HIV-1 mRNA. While 10–
20 μM AdOx is sufficient to generate hypomethylated pro-
teins in cells (1) [see [21,45]], many studies use much
higher concentrations (0.1–1 mM). We avoided very high
levels of AdOx as they have been shown to be associated
with defects in cell cycle progression, cell apoptosis, and
necrosis [46], and resulted in cell toxicity.
In an attempt to identify which viral proteins (other than
Tat) were involved in the observed effects on HIV-1 infec-
tivity after addition of AdOx, the HIV-1 viral mutant
NL4.3VprFS was used. This virus lacks a functional vpr
gene due to a frameshift mutation at amino acid 63 in the
vpr open reading frame. The accessory viral protein Vpr
has been shown to be involved in viral transactivation by
acting as a transcriptional activator [47], in the nuclear
import of the pre-integration complex [37] allowing rep-
lication of HIV-1 in non-dividing cells [48], as well as in
other activities like regulation of apoptosis and cell cycle
arrest [49-53]. Because protein methylation has been
described in several of these cellular events, most impor-
tantly the regulation of transcription [6-8] and nuclear
transport [11], and Vpr possesses two predicted methyla-
tion sites (at amino acid R84 and R87) and is incorpo-
rated into virions, it is a likely candidate to be involved in
the methylation-dependent regulation of infectivity. If
Vpr itself needs to be methylated in order to maintain suf-
ficient infectivity, then infectivity of virus lacking Vpr
(NL4.3VprFS) should not be affected by the presence of
AdOx. Interestingly, our infectivity results with
NL4.3VprFS virus produced in the presence of AdOx indi-
cate that the observed decreases in infectivity were due to
inhibition of a protein other than Vpr. In the absence of
Vpr, decreases in infectivity after AdOx treatment were
more pronounced than in virus containing Vpr. In addi-
tion, differences between infectivity in dividing and
growth arrested MAGI-X4 cells were more pronounced in
the absence of Vpr. A differential effect on infectivity in
dividing and growth arrested MAGI-X4 cells suggests an
effect on PIC nuclear transport. Vpr, MA and IN have been
suggested to be involved in PIC nuclear transport possibly
in a redundant fashion [37]. One possible explanation for
the differential infectivity in dividing and growth arrested
MAGI-X4 cells in the absence of Vpr could be that one of
the other proteins that can compensate for Vpr function in
terms of PIC transport and/or nuclear import needs to be
methylated in order to fulfill this function. In the absence
of Vpr in NL4.3VprFS virus and in the absence of sufficient
protein methylation, a compounding decrease in infectiv-
ity in particular in growth arrested cells, as observed in
this study, would be the result. These data further support
that multiple, complex and possibly opposing and/or
redundant mechanisms of protein methylation are likely
involved in regulating HIV-1 infectivity.
We also determined the infectivity of virus lacking the
HIV-1 envelope glycoprotein using VSV-G pseudotyped
virus produced in HEK293 cells in the presence of AdOx.
Importantly, we demonstrated that the decreased infectiv-
ity in the presence of AdOx was completely restored to
wild type levels when HIV-1 Env was replaced by VSV-G.
One possibility is that HIV-1 Env methylation might con-
tribute towards virus infectivity, although it is equally
plausible that an endosomal entry pathway bypassed an
early event which was inhibited in virus made by AdOx-
treated cells. However others have reported infectivityRetrovirology 2006, 3:92 http://www.retrovirology.com/content/3/1/92
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defects restored by pseudotyping. For example, an HIV-1
construct containing multiple mutations in MA had
reduced infectivity in MAGI cells, but infectivity could be
restored by pseudotyping HIV-1 with VSV-G [54]. Given
an ERT assay failed to measure significant defects in
reverse transcription, it is distinctly possible there is a
defect somewhere between receptor binding and uncoat-
ing. Deciphering the precise event affected requires further
experiments. In either case, our Western blot data clearly
show that the reduced infectivity after AdOx treatment
was not due to decreased envelope glycoprotein incorpo-
ration into virions, suggesting that the defect is in the early
receptor binding and/or an early entry event. A prediction
of methylation sites within gp160 of NL4.3 using MeMo
identified 10 arginine residues and 28 lysine residues
[57]. Work in our laboratories is currently focusing on
determining which steps of early replication are affected,
if residues in Env are the target by PRMT activity, and if
this accounts for reduced infectivity induced by AdOx
treatment on virus producing cells.
Conclusion
Overall, we have shown that protein methylation contrib-
utes towards maximal virus infectivity. Furthermore, our
results also indicate that protein methylation regulates
HIV-1 infectivity in a complex manner most likely involv-
ing the methylation of multiple viral or cellular proteins
and/or multiple steps of replication. With the increased
knowledge of the importance of protein methylation in a
wide range of cellular events, it is important to fully deter-
mine the exact role and mechanism of both viral protein
methylation and methylation of cellular proteins
involved in virus replication. This information will be
essential in order to investigate whether regulation of pro-
tein methylation may be considered a potential target for
future novel antivirals in the combat of HIV-1 and possi-
bly other viral infections.
Methods
Cell lines
CEM cells (acute lymphoblastic T-cell leukaemic cells)
were maintained in Dulbeccos RPMI 1640 supplemented
with 10% FBS, 100 U/ml penicillin and 0.1 mg/ml strep-
tomycin. HEK 293T cells (human embryonic kidney
cells), HEK293, and the HeLa derived MAGI-X4 cell lines
were maintained in DMEM containing 10% FCS, 100 U/
ml penicillin, 0.1 mg/ml streptomycin and 2 mM L-
glutamine. Media for the MAGI-X4 cells also contained
G418 (0.2 mg/ml), hygromycin B (0.1 mg/ml) and puro-
mycin (1 μg/ml). Chinese hamster ovary cells (CHO) and
CHO stably expressing ENV, kindly provided by Andreas
Suhrbier, were cultured in RPMI 1640 supplemented with
10% FBS, 100 U/ml penicillin and 0.1 mg/ml streptomy-
cin
Virus production, purification and quantitation
The molecular cloned HIV-1 virus pNL4.3 and a
frameshift mutant of pNL4.3 resulting in a Vpr-negative
HIV-1 variant (pNL4.3VprFS) were used in this study.
Virus was obtained either from HEK293T cells transfected
with 9 μg maxi-prep DNA (QIAGEN) using lipofectamine
2000 (Invitrogen) or from infected CEM cells. For pseudo-
typed HIV-1, HEK293 cells were transfected with 6.5 μg
pNL4.3.LUC.RE and 1.5 μg of pHEF-VSVG (Both NIH Ref-
erence and Reagents Program), or 8 μg of pNL4.3. The
amount of virus in filtered, infectious supernatants was
measured using either a CAp24 ELISA (Zeptometrix), a
functional reverse transcriptase (RT) assay (RT Detect
from Roche) or an in-house RT assay as previously
described [55,56]. Virus was pelleted either through a
20% sucrose cushion via ultracentrifugation at 100,000 ×
g for 2 h at 4°C, or at 20,000 × g for 2 h at 4°C. Cell lysates
were prepared from both infected CEM and transfected
HEK293T cells. The former were lysed in 1X RIPA buffer
(50 mM Tris-HCl (pH 8.0), 150 mM NaCl, containing 1%
TritonX-100, 0.1% SDS, 0.5% sodium deoxycholate, 2 μg/
ml pepstatin A and 1 tablet of Complete, EDTA- free pro-
tease inhibitor cocktail tablets/50 ml buffer (Roche), and
the later in 1X PBS containing 1% Triton-X100 and pro-
tease inhibitor cocktail.
Western blotting
Pelleted virus was lysed in either RT lysis buffer (50 mM
Tris, 80 mM potassium chloride, 2.5 mM DTT, 0.75 mM
EDTA, 0.5% Triton X-100, pH7.8) or in Berman lysis
buffer (0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40
in PBS) containing 1 tablet of complete protease inhibitor
tablet (Roche) per 10 ml, and CAp24 content and RT
activity were measured as described above. An equivalent
amount of virus normalized for Cap24 or RT was then
separated on SDS-PAGE before transferring to PVDF
membranes. Western blots were developed using a mon-
oclonal CAp24 antibody, a polyclonal HIV-Ig or a mono-
clonal gp120 antibody (cat # 4121, 3957 from the NIH
Reference and Reagents Program and cat# ARP3119 from
Ms C Arnold provided through the NIBSC centralized
facility for AIDS Reagents, supported by the EU Pro-
gramme EVA and the UK Medical Research Council,
respectively).
Cell lysates were prepared from CHO, or CHO-ENV cells
using cell RIPA lysis buffer. The protein concentration was
determined by a bradford assay, and 20 μg of protein was
separated by SDS-PAGE on a 4–20% gradient polyacryla-
mide gel. The protein was transferred to a PVDF mem-
brane and probed using an HIV-Ig at 1:2000 dilution, or a
goat anti-HIV-1 polyclonal antibody (BioDesign) at a
1:1000 dilution. The HEK293T lysates were prepared with
Berman lysis buffer and similarly probed using an anti-
dimethyl-arginine antibody (ASYM24, Upstate) at aRetrovirology 2006, 3:92 http://www.retrovirology.com/content/3/1/92
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1:1000 dilution. Each antibody was detected using an
appropriate horse radish peroxidase (HRP) or Alkaline
Phosphatase-conjugated secondary antibody and Super-
Signal West Pico chemiluminescent substrate (Pierce) or
BCIP/NBT substrate (Sigma).
Infections in CEM cells
For virus production from CEM cells, ~1.3 × 105 CEM
cells/ml were co-cultured with ~5 × 104 cells/ml chroni-
cally HIV-1 infected CEM cells. Virus production was
monitored visually for cytopathic effects and by CAp24
ELISA. AdOx experiments were performed 8 days post co-
culture.
Treatment with AdOx
Adenosine periodate (Sigma) was solubilized at 1 or 15
mM stock concentration in milliQ H2O, stored frozen and
added at various times to the cultured cells at the indi-
cated final concentrations. For assessment of CEM viabil-
ity in the presence of AdOx, 7 × 105 CEM cells/ml were
grown in the presence of various concentrations of AdOx
for 24 hours. Thereafter, the media was replaced with
fresh media containing AdOx and the cells were grown for
a further 24 hours prior to assessing viability using a
trypan blue exclusion assay and a hemocytometer. Treated
and untreated virus supernatant was collected and passed
through a 0.45 μm filter. For virus production from trans-
fected HEK293T cells, AdOx was initially added 4–6 hours
after transfection. Thereafter, the media and AdOx were
replaced 24 h post transfection and viral supernatants
were collected at 48 hours post transfection and filtered
through 0.45 μm filters.
Infectivity assay
The single round infectivity assay in the MAGI-X4 cell line
was used to compare infectivity of virus produced from
infected CEM and transfected HEK293T or HEK293 cells
in the presence or absence of AdOx. MAGI-X4 cells were
seeded in 6 or 24 well plates one day prior to infection.
Virus normalized to RT was added in a total volume of
200–500 μL for 2–4 h, and cells were grown for an addi-
tional 48 hours before fixing and staining with X-gal for β-
galactosidase activity. Blue foci, indicative of infected cells
were counted under a light microscope. MAGI-X4 cells
were infected with virus obtained in the presence or
absence of AdOx from CEM, HEK293T, or HEK293 cells.
This infectivity assay was also conducted in MAGI-X4 cells
pre-treated with AdOx at a single dose of 10 μM either 6 h
or 24 h prior to infection with virus obtained from cells
not treated with AdOx. Infectivity in growth arrested (via
γ-irradiation at 6000 Rad) MAGI-X4 cells was also
assessed using the same virus inocula as before.
Transmission electron microscopy
To assess the effect of AdOx on HIV-1 infected CEM cells
by Transmission Electron Microscopy (TEM), the cells (7
× 105 cells/ml) were grown in the presence or absence of
20  μM AdOx for 24 hours. Thereafter, the media was
replaced with fresh media containing AdOx and the cells
were grown for a further 24 hours. These treatments were
performed in parallel with the CEM AdOx treatments
described above. The cells were harvested by centrifuga-
tion, washed once with PBS, then each pellet was resus-
pended in 2 ml of 3% glutaraldehyde in 0.1 M sodium
phosphate buffer (pH 7.4) and incubated at room tem-
perature for 2 h. The cells were washed with 0.1 M sodium
phosphate buffer and treated with 1% osmium tetroxide
in 0.1 M sodium cacodylate buffer for 40 minutes at room
temperature. The cells were next washed with 0.1 M
sodium cacodylate buffer, followed by 80% acetone and
stained with 2% uranyl acetate in 80% acetone overnight
at 4°C. The pellets were then dehydrated, embedded in
epon resin and polymerized at 65°C. 100 nm thick sec-
tions were cut and EM grids (on 200 mesh copper) (Pro-
SciTech) were prepared for each sample. Each grid
(containing 4–5 sections) was stained with 5% uranyl ace-
tate, followed by lead citrate, rinsed with distilled water
and then visualized by TEM. The staining, epon embed-
ding, ultramicrotomy and TEM analysis were performed
by Deborah Stenzel at the Analytical Electron Microscopy
Facility, The Queensland University of Technology.
ERT assay
Reverse transcription products were generated by addition
of virus particles to a mixture (final volume of 50 μl) con-
taining 10 mM Tris, pH 7.4, 10 mM MgCl2, 500 U/ml
DNase I (unless otherwise indicated) and 200 μM of each
dNTP in RPMI1640 medium for up to 20 h as indicated.
Triton X-100 and AdOx were included at the concentra-
tions indicated in the text. A no nucleotide control reac-
tion was always included. Products were extracted, once
with an equal phenol:chloroform:iso-amyl alcohol
(25:24:1) and once with chloroform. The extracts were
ethanol precipitated, washed with 70% ethanol, dried and
resuspended in 100 μl of 0.1 mM EDTA. Purified reaction
products (5 μl) were added to the reaction mix containing
0.4 μM of each primer, SYBR Green I, 30 U/ml Platinum
Taq polymerase, 20 mM Tris-HCl pH 8.4, 50 mM KCl, 3
mM MgCl2, 200 μM each dNTP, 20 U/l uracil-N-glycosy-
lase (Invitrogen, Carlsbad, CA, USA) in a final volume of
15 μl. A no-DNA control (5 μl of 0.1 mM EDTA, pH 8.0)
was also included. Standard primer sets used for amplifi-
cation were strong-stop DNA reverse (5'-d AAGCAGT-
GGGTTCCCTAGTTAG-3') and forward (5'-d
GGTCTCTCTGGTTAGACCA-3') oligonucleotides. The
mixes were subjected to cycling: [50°C, 2 min; 95°C, 2
min]1 [95°C, 15 sec; 65°C, 30 sec]40 on a Rotor-Gene
3000™ thermocycler (Corbett) set to collect SYBR fluores-Retrovirology 2006, 3:92 http://www.retrovirology.com/content/3/1/92
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cent signal after the 65°C step. Copy number was deter-
mined by reference to a standard curve prepared by
dilution of plasmid DNA (NL4.3 strain). A no-nucleotide
control was always included and was negligible or the
data were discarded. Total RT activity in each virus super-
natant was measured using the Roche RT Detect assay and
this value was used to normalize measured DNA copies.
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